A Study of LY4175408 in People With Solid Tumor Cancer

Full Title

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-ExpressingTumor Cells, in Participants with Selected Advanced Solid Tumors

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Yonina Murciano-Goroff’s office at 646-888-4226.

Protocol

26-053

Phase

Phase I (phase 1)

Investigator

Yonina R. Murciano-Goroff

Co-Investigators

Robert Maki

Diseases

Breast Cancer
Gynecologic Cancer › Uterine (Endometrial) Cancer
Lung Cancer › Lung Cancer, Non-Small Cell
Lung Cancer › Lung Cancer, Small Cell

Locations

Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau

ClinicalTrials.gov ID

NCT07046923

ClinicalTrials.gov

Visit ClinicalTrials.gov for full clinical trial description